| Status: Medicine does not meet criteria for AWMSG assessment | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA986: Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over |
|
Medicine details |
|
| Medicine name | lebrikizumab (Ebglyss®) |
| Formulation | 250 mg solution for injection in pre-filled pen |
| Reference number | 4437 |
| Indication | For the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and older with a body weight of at least 40 kg who are candidates for systemic therapy |
| Company | Almirall Limited |
| BNF chapter | Skin |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 31/05/2024 |
| NICE guidance | TA986: Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over |